Shkreli hit with $64.6M verdict, lifetime pharma ban in antitrust case

About a month after Martin Shkreli's former company inked a $40 million settlement to resolve allegations of anticompetitive conduct on toxoplasmosis drug Daraprim, the "pharma bro" has learned his fate in his own antitrust case.